- Home
- IDR vs CYBN Comparison
IDR vs CYBN Comparison
Compare IDR & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- CYBN
- Stock Information
- Founded
- IDR 1996
- CYBN 2019
- Country
- IDR United States
- CYBN Canada
- Employees
- IDR N/A
- CYBN N/A
- Industry
- IDR Precious Metals
- CYBN Pharmaceuticals and Biotechnology
- Sector
- IDR Basic Materials
- CYBN Health Care
- Exchange
- IDR Nasdaq
- CYBN Nasdaq
- Market Cap
- IDR 154.1M
- CYBN 174.9M
- IPO Year
- IDR N/A
- CYBN N/A
- Fundamental
- Price
- IDR $13.76
- CYBN $7.71
- Analyst Decision
- IDR Strong Buy
- CYBN Strong Buy
- Analyst Count
- IDR 1
- CYBN 4
- Target Price
- IDR $17.50
- CYBN $86.00
- AVG Volume (30 Days)
- IDR 315.9K
- CYBN 310.7K
- Earning Date
- IDR 07-29-2025
- CYBN 08-07-2025
- Dividend Yield
- IDR N/A
- CYBN N/A
- EPS Growth
- IDR 144.40
- CYBN N/A
- EPS
- IDR 0.62
- CYBN N/A
- Revenue
- IDR $27,144,971.00
- CYBN N/A
- Revenue This Year
- IDR $9.76
- CYBN N/A
- Revenue Next Year
- IDR N/A
- CYBN N/A
- P/E Ratio
- IDR $22.27
- CYBN N/A
- Revenue Growth
- IDR 67.42
- CYBN N/A
- 52 Week Low
- IDR $8.90
- CYBN $4.81
- 52 Week High
- IDR $19.75
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- IDR 48.18
- CYBN 50.59
- Support Level
- IDR $14.00
- CYBN $7.50
- Resistance Level
- IDR $14.79
- CYBN $9.20
- Average True Range (ATR)
- IDR 0.62
- CYBN 0.56
- MACD
- IDR 0.13
- CYBN -0.12
- Stochastic Oscillator
- IDR 43.72
- CYBN 27.06
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.